KLA Corp (NASDAQ:KLAC) is highlighted as a strong candidate for an "Affordable Growth" investment strategy, characterized by its balance of robust growth and reasonable valuation. The company demonstrates strong growth in EPS and revenue, excellent profitability with high margins, and a healthy financial position, all while trading at a P/E ratio significantly lower than the broader market and many peers. This makes KLAC appealing for investors seeking growth without overpaying, as identified by the ChartMill "Affordable Growth" screen.

IBM recently announced a significant US$10 billion investment in quantum computing over five years, along with other AI-focused initiatives and partnerships. This move reinforces IBM's strategy to embed its hybrid cloud, AI, and quantum technologies in enterprise and workforce transformation, aiming to offset pressures in consulting and legacy services. While exciting, investors should consider the implications of rising competition and IBM's high debt in light of these long-term technology bets.

Clal Insurance Enterprises Holdings Ltd significantly increased its stake in The Walt Disney Company (DIS) by 33.2% in the fourth quarter, bringing its total holdings to 638,121 shares valued at approximately $72.79 million. Other institutional investors like Norges Bank and Viking Global Investors also added substantial positions, indicating strong institutional interest with hedge funds and asset managers owning about 65.71% of the stock. Wall Street analysts maintain a "Moderate Buy" rating for Disney with an average price target of $133.71, supported by positive earnings estimates and operational improvements.

Cullen Capital Management LLC reduced its stake in Keurig Dr Pepper (NASDAQ:KDP) by 3.1% in the fourth quarter, selling 47,446 shares. Despite this trim, institutional ownership remains high at 93.99%, with several other firms increasing their positions. Wall Street analysts have a mixed but cautiously positive outlook, with an average "Hold" rating and a consensus price target of $32.00, while KDP recently announced a quarterly dividend of $0.23 per share.

Boston Partners increased its stake in T-Mobile US (TMUS) by 10% in Q4, acquiring an additional 211,332 shares, bringing its total holdings to 2.33 million shares valued at $471.7 million. T-Mobile continues to receive strong institutional and analyst support, holding a "Moderate Buy" consensus rating and a target price of $260.48. The company reported robust quarterly results, surpassing EPS estimates with $2.27 per share and achieving 10.6% year-over-year revenue growth, while also distributing a quarterly dividend of $1.02 per share.

Cullen Capital Management LLC reduced its stake in Verizon Communications Inc. by 18% in the fourth quarter, holding 1.26 million shares valued at $51.35 million. Verizon reported Q1 earnings above estimates and reaffirmed its FY2026 EPS guidance, along with declaring a quarterly dividend of $0.7075 per share, yielding approximately 5.9%. Despite an insider selling a significant portion of shares, Wall Street analysts generally maintain a "Moderate Buy" rating with an average target price of $50.59 for the company.

Dynamic Technology Lab Private Ltd has acquired 6,565 shares of Williams-Sonoma, Inc. (WSM) worth approximately $1.17 million. This purchase is part of significant institutional ownership in the company, with hedge funds holding 99.29% of its stock. The company recently reported strong quarterly earnings, beating estimates, and announced a quarterly dividend of $0.76 per share.

Cullen Capital Management LLC reduced its stake in International Business Machines (IBM) by 9.6% in the fourth quarter, selling 16,412 shares and bringing its total holdings to 154,588 shares valued at $45.8 million. This comes as IBM reported strong quarterly results, exceeding analyst expectations with EPS of $1.91 and revenue of $15.92 billion, a 9.5% year-over-year increase. Analysts generally rate IBM as a "Moderate Buy" with a consensus price target of $304.17, and the company recently raised its quarterly dividend to $1.69 per share.

Dr Reddy's Laboratories has launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, securing 180 days of market exclusivity. This strategic launch, developed in collaboration with MSN Laboratories, expands Dr Reddy's oncology portfolio and aims to make critical treatments more accessible. The reference brand, Bosulif, reported US sales of $253.8 million in the 12 months ending April 2026.

Gator Capital Management LLC significantly increased its stake in Primerica, Inc. (NYSE:PRI) by 1,311.3% during the fourth quarter, now holding 11,149 shares valued at $2.88 million. Other institutional investors also adjusted their positions, and Primerica reported strong quarterly earnings, surpassing analyst expectations for EPS and revenue. The company also announced a quarterly dividend of $1.20 per share.